Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis.

Authors: Ricart, JM  Ramon, LA  Vaya, A  Espana, F  Santaolaria, ML  Todoli, J  Castello, R  Fontcuberta, J  Estelles, A 
Citation: Ricart JM, etal., Br J Haematol. 2008 May;141(5):716-9. doi: 10.1111/j.1365-2141.2008.07078.x. Epub 2008 Mar 12.
Pubmed: (View Article at PubMed) PMID:18341631
DOI: Full-text: DOI:10.1111/j.1365-2141.2008.07078.x

This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behcet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0.001) and plasminogen activator inhibitor-1 (PAI-1) levels (P = 0.022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0.024). In conclusion, the increased TAFI levels in Behcet disease could contribute to the increased risk of thrombosis observed in these patients.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 8547693
Created: 2014-02-19
Species: All species
Last Modified: 2014-02-19
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.